ILMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Illumina Inc (ILMN) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has shown solid financial performance in the latest quarter and has some positive catalysts, the lack of strong trading signals, insider selling trends, and mixed analyst sentiment suggest holding off on immediate investment.
The technical indicators show a neutral to mildly bullish trend. The MACD is above 0 and positively contracting, the RSI is neutral at 51.458, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 122.723, with resistance at 127.552 and support at 117.895.
Illumina's Q4 2025 financials showed strong YoY growth in revenue (+4.98%), net income (+78.61%), and EPS (+84.75%).
The company's pricing remains competitive compared to Roche's Xpandomer-based nanopore sequencer, which is a near-term positive.
Analysts have raised price targets recently, with some maintaining Buy or Overweight ratings.
Insiders are selling heavily, with a 287.98% increase in selling activity over the last month.
Hedge funds are neutral, indicating no strong institutional support.
The broader market (S&P
is down -1.79%, reflecting a bearish sentiment.
In Q4 2025, Illumina reported revenue of $1.159 billion (+4.98% YoY), net income of $334 million (+78.61% YoY), and EPS of 2.18 (+84.75% YoY). However, gross margin declined slightly to 65.49% (-0.68% YoY). Overall, the financials indicate strong growth trends.
Analysts have mixed views. Piper Sandler lowered the price target to $170 from $195 but maintained an Overweight rating. JPMorgan lowered the price target to $120 from $130 with a Neutral rating. UBS raised the target to $135 from $120 with a Neutral rating, while Evercore ISI and Guggenheim raised their targets and maintained positive ratings. The consensus indicates cautious optimism but no unanimous bullish sentiment.
